Cargando…

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma

Immune checkpoint inhibitors (ICI) have drastically changed the landscape of metastatic melanoma management, thus significantly improving survival. Clinically, assessing treatment response may be challenging in a portion of cases due to a massive influx of immune cells into the tumor microenvironmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia, Diogo, Beal, Juliana Rodrigues, Alvarez, Daniel Mamere, Macarenco, Ricardo Silvestre e Silva, Schvartsman, Gustavo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255661/ https://www.ncbi.nlm.nih.gov/pubmed/34248554 http://dx.doi.org/10.1159/000516036

Ejemplares similares

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Management of metastatic cutaneous melanoma: updates in clinical practice
por: Schvartsman, Gustavo, et al.
Publicado: (2019)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
por: Poindexter, Bradley C, et al.
Publicado: (2022)

Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma
por: Oliveira, Leandro J. C., et al.
Publicado: (2018)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
por: Jia, Wenxiao, et al.
Publicado: (2019)

Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma - Part II
por: Castro, Luiz Guilherme Martins, et al.
Publicado: (2016)

Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report
por: Liu, Guihong, et al.
Publicado: (2018)

Pseudoprogression in lung cancer: a case report
por: Meoni, Giulia, et al.
Publicado: (2020)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma - Part I
por: Castro, Luiz Guilherme Martins, et al.
Publicado: (2015)

Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
por: Li, Yan, et al.
Publicado: (2021)

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
por: Xiang, Yongbo, et al.
Publicado: (2023)

Anthropometry in the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Cutaneous melanoma and the immunotherapy revolution (Review)
por: Leonardi, Giulia C., et al.
Publicado: (2020)

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression
por: Jia, Wenxiao, et al.
Publicado: (2021)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
por: Moliner, Laura, et al.
Publicado: (2020)

Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review)
por: Volovat, Simona Ruxandra, et al.
Publicado: (2021)

Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
por: Zhang, Xiaojie, et al.
Publicado: (2021)

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review
por: Chae, Young Kwang, et al.
Publicado: (2017)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
por: Schvartsman, Gustavo, et al.
Publicado: (2017)

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
por: Sadozai, Hassan, et al.
Publicado: (2017)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Cutaneous Events Associated with Immunotherapy of Melanoma: A Review
por: Burzi, Lorenza, et al.
Publicado: (2021)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
por: Nikolaou, Vasiliki, et al.
Publicado: (2023)

Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Reticulated acanthoma with sebaceous differentiation mimicking melanoma
por: Ribeiro, Felipe, et al.
Publicado: (2017)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
por: Suyanto, Suyanto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ubq9vu2bfmni0vetk9hcj2ckt7